Versant Venture Management, LLC
SEC exempt reporting adviser (venture capital exemption).
- HQ
- CA
Versant Venture Management, LLC builds biotechnology companies with academic founders through in-house discovery engines of multi-disciplinary scientists working in laboratory facilities. Its team includes a chairman, managing directors, partners, venture partners, and principals, many with Ph.D. backgrounds. Portfolio companies listed include AllRock Bio, Dualitas, Helicore Biopharma, Antag Therapeutics, Pep2Tango Therapeutics, Borealis Biosciences, Vector BioPharma AG, Vividion Therapeutics, Black Diamond Therapeutics, and Turnstone Biologics.
New fund likely raising soon
The firm's newest fund is 4 to 7 years past its first sale and no newer Form D has been filed.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Not stated | Not enough dated deals | Growth, Series B, Series A |
| Sectors | Biotech | Not enough dated deals | Healthtech, Biotech, Medical devices |
| Regions | Not stated | Not enough dated deals | CA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2000 | 3 | Biotech, Data analytics, Digital health |
| 2001 | 8 | Biotech, Healthtech, Data analytics |
| 2002 | 12 | Healthtech, Biotech, Medical devices |
| 2003 | 8 | Biotech, Healthtech, Medical devices |
| 2004 | 19 | Healthtech, Biotech, Medical devices |
| 2005 | 14 | Biotech, Healthtech, Medical devices |
| 2006 | 24 | Healthtech, Biotech, Medical devices |
| 2007 | 20 | Healthtech, Biotech, Medical devices |
| 2008 | 26 | Healthtech, Biotech, Medical devices |
| 2009 | 21 | Biotech, Healthtech, Medical devices |
| 2010 | 10 | Healthtech, Biotech, Medical devices |
| 2011 | 15 | Healthtech, Medical devices, Biotech |
| 2012 | 19 | Healthtech, Medical devices, Biotech |
| 2013 | 15 | Healthtech, Biotech, Medical devices |
| 2014 | 16 | Healthtech, Biotech, Medical devices |
| 2015 | 16 | Healthtech, Biotech, Medical devices |
| 2016 | 8 | Healthtech, Biotech, Medical devices |
| 2017 | 15 | Biotech, Healthtech, Medical devices |
| 2018 | 17 | Biotech, Healthtech, Life sciences and research tools |
| 2019 | 14 | Biotech, Healthtech, Digital health |
| 2020 | 5 | Biotech, Healthtech, Digital health |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2010 | 0 | 0 | 2 | 5 | 3 |
| 2011 | 0 | 0 | 0 | 1 | 11 |
| 2012 | 0 | 0 | 1 | 3 | 7 |
| 2013 | 0 | 0 | 6 | 2 | 6 |
| 2014 | 0 | 0 | 4 | 4 | 6 |
| 2015 | 0 | 0 | 7 | 3 | 4 |
| 2016 | 0 | 0 | 2 | 2 | 2 |
| 2017 | 0 | 0 | 6 | 4 | 4 |
| 2018 | 0 | 0 | 8 | 5 | 3 |
| 2019 | 0 | 0 | 4 | 7 | 3 |
| 2020 | 0 | 0 | 3 | 2 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Versant Vantage III, L.P. Versant builds biotechnology companies with academic founders through in-house discovery engines of multi-disciplinary scientists working in state-of-the-art laboratory facilities. Portfolio examples include clinical programs in pulmonary hypertension and obesity. Inferred from the firm's website and portfolio companies | 2022 | $298.65M to $310.72M (Form D and SEC adviser filing) | Late investment period |
| Versant Venture Capital IX, L.P. Versant builds biotechnology companies with academic founders through in-house discovery engines of multi-disciplinary scientists working in state-of-the-art laboratory facilities. Portfolio examples include clinical programs in pulmonary hypertension and obesity. Inferred from the firm's website and portfolio companies | 2022 | $600.36M to $619.5M (Form D and SEC adviser filing) | Late investment period |
| Versant Voyageurs III, L.P. Versant builds biotechnology companies with academic founders through in-house discovery engines of multi-disciplinary scientists working in state-of-the-art laboratory facilities. Portfolio examples include clinical programs in pulmonary hypertension and obesity. Inferred from the firm's website and portfolio companies | 2022 | $300.18M to $309.95M (Form D and SEC adviser filing) | Late investment period |
| Versant Vantage II, L.P. | 2020 | $253.86M (Form D) | Follow-ons only |
| Versant Venture Capital VIII, L.P. | 2020 | $560.24M (Form D) | Follow-ons only |
| Versant Voyageurs II, L.P. | 2020 | $140.06M (Form D) | Follow-ons only |
03 · People across funds
- Alex Mayweg, Managing Director of the Ultimate General Partner
Versant Vantage III, L.P. (Named on Form D); Versant Venture Capital IX, L.P. (Named on Form D); Versant Voyageurs III, L.P. (Named on Form D); Versant Vantage II, L.P. (Named on Form D); Versant Venture Capital VIII, L.P. (Named on Form D); Versant Voyageurs II, L.P. (Named on Form D)
- Bradley Bolzon, Managing Director of the Ultimate General Partner
Versant Vantage III, L.P. (Named on Form D); Versant Venture Capital IX, L.P. (Named on Form D); Versant Voyageurs III, L.P. (Named on Form D); Versant Vantage II, L.P. (Named on Form D); Versant Venture Capital VIII, L.P. (Named on Form D); Versant Voyageurs II, L.P. (Named on Form D)
- Carlo Rizzuto, Managing Director of the Ultimate General Partner
Versant Vantage III, L.P. (Named on Form D); Versant Venture Capital IX, L.P. (Named on Form D); Versant Voyageurs III, L.P. (Named on Form D); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Clare Ozawa, Managing Director of the Ultimate General Partner
Versant Vantage III, L.P. (Named on Form D); Versant Venture Capital IX, L.P. (Named on Form D); Versant Voyageurs III, L.P. (Named on Form D); Versant Vantage II, L.P. (Named on Form D); Versant Venture Capital VIII, L.P. (Named on Form D); Versant Voyageurs II, L.P. (Named on Form D)
- Jerel Davis, Managing Director of the Ultimate General Partner
Versant Vantage III, L.P. (Named on Form D); Versant Venture Capital IX, L.P. (Named on Form D); Versant Voyageurs III, L.P. (Named on Form D); Versant Vantage II, L.P. (Named on Form D); Versant Venture Capital VIII, L.P. (Named on Form D); Versant Voyageurs II, L.P. (Named on Form D)
- Robin Praeger, Managing Director of the Ultimate General Partner
Versant Vantage II, L.P. (Named on Form D); Versant Venture Capital VIII, L.P. (Named on Form D); Versant Voyageurs II, L.P. (Named on Form D)
- Thomas Woiwode, Managing Director of the Ultimate General Partner
Versant Vantage III, L.P. (Named on Form D); Versant Venture Capital IX, L.P. (Named on Form D); Versant Voyageurs III, L.P. (Named on Form D); Versant Vantage II, L.P. (Named on Form D); Versant Venture Capital VIII, L.P. (Named on Form D); Versant Voyageurs II, L.P. (Named on Form D)
- Alicia Levey, Venture Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Ariel Kantor, Principal
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Brad Bolzon, Chairman, Managing Director
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Joel Drewry, Principal
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Kevin Grove, Venture Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Markus Enzelberger, Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Mehmet Badur, Principal
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Michael Wong, Principal
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Monal Mehta, Venture Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Nigel Sheail, Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Nikita Sharma, Principal
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Peter Emtage, Venture Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Rami Hannoush, Venture Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Richard Glynne, Venture Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Tom Hudson, Venture Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Tom Woiwode, Managing Director
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Zach Sweeney, Venture Partner
Versant Vantage III, L.P. (Team); Versant Venture Capital IX, L.P. (Team); Versant Voyageurs III, L.P. (Team); Versant Vantage II, L.P. (Team); Versant Venture Capital VIII, L.P. (Team); Versant Voyageurs II, L.P. (Team)
- Alex Mayweg, Ph.D., Managing Director
On the team page, not linked to a fund
- Ariel Kantor, Ph.D., Principal
On the team page, not linked to a fund
- Brad Bolzon, Ph.D., Chairman, Managing Director
On the team page, not linked to a fund
- Carlo Rizzuto, Ph.D., Managing Director
On the team page, not linked to a fund
- Clare Ozawa, Ph.D., Managing Director
On the team page, not linked to a fund
- Jerel Davis, Ph.D., Managing Director
On the team page, not linked to a fund
- Joel Drewry, Ph.D., Principal
On the team page, not linked to a fund
- Markus Enzelberger, Ph.D., Partner
On the team page, not linked to a fund
- Mehmet Badur, Ph.D., Principal
On the team page, not linked to a fund
- Michael Wong, Ph.D., Principal
On the team page, not linked to a fund
- Tom Woiwode, Ph.D., Managing Director
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- HTTP://WWW.VERSANTVENTURES.COM/
- http://www.versantventures.com/news
- http://www.versantventures.com/team
- http://www.versantventures.com/
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026